Axonis Therapeutics is a biotechnology company dedicated to developing innovative neuromedicines, particularly first-in-class therapies for neurological disorders. The company's lead candidate, AXN-027, is an oral small molecule aimed at enhancing the function of KCC2, a key CNS chloride transporter, to treat conditions such as epilepsy and pain. Additionally, Axonis is focused on advancing next-generation compounds targeting KCC2 for various neurological, psychiatric, and neurodevelopmental disorders.
Leadership & Board
Current Number of Employees29
Current LinkedIn Followers6,416
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$115M
Total Amount Raised$115M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$115M
Latest Funding Amount$115M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Axonis Therapeutics had 29 employees as of September 28, 2026. The number of employees increased by 1 (3.57%) week-over-week.
29Latest Employee Count
1(3.57%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Axonis Therapeutics had 6,416 followers as of September 28, 2026. The number of followers increased by 105 (1.66%) week-over-week.
6,416Latest Followers Count
105(1.66%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.
Funding Round
Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Aug 14, 2025
Series A
$115.00M
―
Similar Companies
A snapshot of private companies similar to Axonis Therapeutics, helping you discover and navigate related company profiles.